A brief analysis of the new drug secrexizotinib for non-small cell lung cancer

brief analysis of the new drug secrexizotinib for non-small cell lung cancer
?
Targeted therapy is at the cellular and molecular level, targeting the identified carcinogenic site (the site can be inside the tumor cell) A protein molecule, or a gene fragment) to design corresponding therapeutic drugs. When targeted drugs enter the human body, they will specifically select carcinogenic sites to bind and act, causing tumor cells to specifically die without affecting normal tissue cells surrounding the tumor. Molecular targeted therapy, also known as biological missiles, is more selective, more effective, and less toxic than chemotherapy.
?
The traditional R (representing the drugs Irexatrocetin, etc.) is only suitable for patients with R mutations. Not only is it ineffective against mutations or R (RRR) mutations, blind use may even have adverse effects. The effect is to make the disease progress rapidly. With the deepening of research on targeted drugs, targeted drugs targeting mutations and R mutations have been approved for marketing or are in clinical trials.
?
Sekreli, commonly known as crizotinib, is a targeted drug for positive tumors. According to relevant studies, one case of non-small cell lung cancer was positive. In other words, about % of non-small cell lung cancer patients will benefit from the launch of Xalkori. Crizotinib, a small molecule inhibitor targeting gene targets, is a competitive tyrosinase inhibitor that can specifically target inhibition. Clinical trials have shown that for patients with positive advanced disease, the efficacy of crizotinib is significantly better than traditional chemotherapy, with an objective response rate of % (compared to % of chemotherapy). At present, the drug has been approved for marketing in China. Domestic patients can benefit from the drug, but it needs to be emphasized that the prerequisite for the drug's use is mutation.
?
Androidgen, commonly known as r, is a small molecule targeted drug targeting R gene mutations or high expression of R genes. The phase I clinical trial of Androgen showed that during the consecutive weeks of the study, all patients in the dose escalation group (/) and standard dose (and/) showed no dose-limiting toxicity, demonstrating the good safety and tolerability of Androgen sex, and the % improvement rate shows that Androgen has a good inhibitory effect on advanced lung adenocarcinoma. Currently, the drug is still undergoing clinical trials and is expected to be approved for marketing as soon as this year. It is reported that through clinical plans, domestic patients may be able to take medication in advance and benefit from the drug. It should be emphasized that the prerequisite for the use of this drug is R mutation or high R expression.
?
Obviously, with the progress of molecular medicine and the in-depth development of targeted drugs, advanced non-small cell lung cancer has entered the era of personalized treatment. Targeted drug experts remind us that before deciding to take targeted drugs, we must do relevant genetic testing, including RR and other items. It is a wise choice to choose targeted drugs based on the results of genetic testing.

Address: Zhongguancun Building, Beisihuan Middle Road, Haidian District, Beijing
Company name: Beijing Mingkang Trading Co., Ltd.
Telephone:
Number:
Contact Person: Miss Chen